Apixaban CAS 503612-47-3

Product Description:

Product Name: Apixaban CAS NO:503612-47-3

Synonyms:

1-(4-methoxyphen yl)-7-oxo-6-[4-(2-oxopiperidin-1-yl)phen yl]-4,5-dihydropyrazolo[3,4-c]pyridine-3-carboxamide;

Chemical & Physical Properties:

Appearance : white crystalline powder

Assay :≥99.0%

Density:1.42g/cm3

Boiling Point:770.5℃ at 760 mmHg

Flash Point:419.8℃

Apixaban is a new type of oral factor Xa inhibitor jointly developed by Bristol-Myers Squibb and Pfizer. It is a new type of oral anticoagulant drug. By inhibiting an important clotting factor Xa, Apixaban can prevent thrombin generation and thrombosis.

On April 26, 2007, Bristol-Myers Squibb and Pfizer announced the cooperation to develop a new oral anticoagulant, apixaban owned by Bristol-Myers Squibb, as an upgraded replacement product for warfarin.

In May 2011, Apixaban was the first to be approved for the prevention of venous thrombosis in adult patients undergoing elective hip or knee replacement surgery in the 27 EU countries, Iceland and Norway.

On November 20, 2012, the European Commission approved aletto (apixaban) for the prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF) with one or more risk factors. Subsequently, the Canadian Drug Administration, Japan, and the US FDA approved (Apixaban) for the prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF) with one or more risk factors.

On April 12, 2013, the new anticoagulant drug ELIQUIS (Apixaban) jointly developed by Bristol-Myers Squibb and Pfizer was officially announced to be launched in China.

If you are interested in our products or have any questions, please feel free to contact us!

Products under patent are offered for R & D purpose only. However, the final responsibility lies exclusively with the buyer.